Vincent L. Giranda

ABT-888, an Orally Active Poly(ADP-Ribose) Polymerase Inhibitor that Potentiates DNA-Damaging Agents in Preclinical Tumor Models

Cherrie K. Donawho, Yan Luo, Yanping Luo et al. · Clinical Cancer Research · 2007 · 773 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

Shivaani Kummar, Robert J. Kinders, Martin Gutierrez et al. · Journal of Clinical Oncology · 2009 · 329 citations · Full text

Medicine, Oncology, Pharmacology +16

Discovering novel ligands for macromolecules using X-ray crystallographic screening

V. Nienaber, Paul L. Richardson, Vered Klighofer et al. · Nature Biotechnology · 2000 · 320 citations

Pharmacy, Chemistry, Medicinal Chemistry +14

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(<i>R</i>)-2-methylpyrrolidin-2-yl]-1<i>H</i>-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

Thomas D. Penning, Gui‐Dong Zhu, Viraj B. Gandhi et al. · Journal of Medicinal Chemistry · 2008 · 269 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Potent and selective inhibitors of Akt kinases slow the progress of tumors <i>in vivo</i>

Yan Luo, Alexander R. Shoemaker, Xuesong Liu et al. · Molecular Cancer Therapeutics · 2005 · 244 citations · Full text

Medicine, Oncology, Pharmacology +15